Abstract:AIM:To explore the relationship between α-fetoprotein (AFP) and various clinicopathological variables and different staging system of hepatocellular carcinoma (HCC) thoroughly. METHODS:A retrospective cohort study of consecutive patients diagnosed with HCC between January 2008 and December 2009 in West China Hospital was enrolled in our study. The association of serum AFP values with the HCC clinicopathological features was analysed by univariate and multivariate analysis, such as status of hepatitis B virus (HBV) infection, tumor size, tumor number, vascular invasion and degree of tumor differentiation. Also, patients were divided into four groups at the time of enrollment according to different cutoff values for serum value of AFP (≤ 20 μg/L, 21-400 μg/L, 401-800 μg/L, and ≥ 801 μg/L), to compare the positive rate of patient among four groups stratified by various clinicopathological variables. And the correlation of different kinds of tumor staging systems, such as TNM, Barcelona Clinic Liver Cancer (BCLC) staging classification and China staging, were compared with the serum concentration of AFP. RESULTS:A total of 2304 HCC patients were enrolled in this study totally; the mean serum level of AFP was 555.3 ± 546.6 μg/L. AFP levels were within the normal range (< 20 μg/L) in 27.4% (n = 631) of all the cases. 81.4% (n = 1875) patients were infected with HBV, and those patients had much higher serum AFP level compared with non-HBV infection ones (573.9 ± 547.7 μg/L vs 398.4 ± 522.3 μg/L, P < 0.001). The AFP level in tumors ≥ 10 cm (808.4 ± 529.2 μg/L) was significantly higher (P < 0.001) than those with tumor size 5-10 cm (499.5 ± 536.4 μg/L) and with tumor size ≤ 5 cm (444.9 ± 514.2 μg/L). AFP levels increased significantly in patients with vascular invasion (694.1 ± 546.9 μg/L vs 502.1 ± 543.1 μg/L, P < 0.001). Patients with low tumor cell differentiation (559.2 ± 545.7 μg/L) had the significantly (P = 0.007) highest AFP level compared with high differentiation (207.3 ± 420.8 μg/L) and intermediate differentiation (527.9 ± 538.4 μg/L). In the multiple variables analysis, low tumor cell differentiation [OR 6.362, 95%CI: 2.891-15.382, P = 0.006] and tumor size (≥ 10 cm) (OR 5.215, 95%CI: 1.426-13.151, P = 0.012) were independent predictors of elevated AFP concentrations (AFP > 400 μg/L). Serum AFP levels differed significantly (P < 0.001) in the D stage of BCLC (625.7 ± 529.8 μg/L) compared with stage A (506.2 ± 537.4 μg/L) and B (590.1 ± 551.1 μg/L). CONCLUSION:HCC differentiation, size and vascular invasion have strong relationships with AFP, poor differentiation and HCC size ≥ 10 cm are independent predictors of elevated AFP. BCLC shows better relationship with AFP.

Prognostic Value of Serum Α‐fetoprotein Level As an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Daily Decrease of Post-Operative Alpha-Fetoprotein by 9% Discriminates Prognosis of HCC: A Multicenter Retrospective Study.

Preoperative Neutrophil-to-lymphocyte Ratio is an Independent Prognostic Predictor for AFP Negative Hepatocellular Carcinoma after Hepatectomy

The Prognostic Value of Alpha-Fetoprotein Ratio in Patients With Resectable Alpha-Fetoprotein-Negative Hepatocellular Carcinoma

Correlation Analysis of Preoperative Serum Alpha-Fetoprotein (AFP) Level and Prognosis of Hepatocellular Carcinoma (HCC) after Hepatectomy

Value of Α-Fetoprotein in Association with Clinicopathological Features of Hepatocellular Carcinoma.

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma

Value of a Scoring System Based on the Serum Levels of Alpha-Fetoprotein and Alkaline Phosphatase in Predic-Ting the Prognosis of Patients with Resectable Hepatocellular Carcinoma

Incorporation of Alpha-Fetoprotein(afp) into Subclassification of BCLC C Stage Hepatocellular Carcinoma According to a 5-Year Survival Analysis Based on the SEER Database.

The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma

Prognostic Significance of Combined Α-Fetoprotein and CA19-9 for Hepatocellular Carcinoma after Hepatectomy

Alpha Fetoprotein Changes Predict Hepatocellular Carcinoma Survival Beyond the Milan Criteria after Hepatectomy.

Alpha-fetoprotein Still is a Valuable Diagnostic and Prognosis Predicting Biomarker in Hepatitis B Virus Infection-Related Hepatocellular Carcinoma.

Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma

Elevated Afp, Atv, And Afp/Atv Ratios As Risk Factors For Poor Prognosis Of Hcc Patients In The Bclc-A Stage

α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.

The significance of serum AFP cut-off values, 20 and 400ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference

Correlation Between Preoperative Serum Alpha-Fetoprotein (AFP) Level and Early Recurrence of Patients with Hepatocellular Carcinoma after Partial Hepatectomy

Prognosis Evaluation in Alpha-Fetoprotein Negative Hepatocellular Carcinoma after Hepatectomy: Comparison of Five Staging Systems